Home > Insider Trading > Filing (0000919574-23-003425)

Filing Details

Accession Number:: 0000919574-23-003425
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-19 21:00:50
Reporting Period:: 2023-05-17

Accepted Time:: 2023-05-19 21:00:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1162194	Standard Biotools Inc.	LAB	Laboratory Analytical Instruments (3826)	770513190

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1891102	Casdin Private Growth Equity Fund Ii, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1919480	Casdin Private Growth Equity Fund Ii Gp, Llc	1350 Avenue Of The Americas, Suite 2600 New York NY 10019	Yes	No	No	No
1938709	Casdin Partners Fo1-Msv, Lp	C/O Casdin Partners Gp, Llc 1350 Avenue Of The Americas, Suite 2600 New York NY 10019	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-17	250,000	$1.89	250,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2023-05-18	150,000	$2.16	400,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2023-05-19	800,000	$2.29	1,200,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.